These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26142191)

  • 1. Flecainide-induced prolongation of ventricular repolarization contributes to the proarrhythmic profile of action.
    Osadchii OE
    Int J Cardiol; 2015 Oct; 197():81-2. PubMed ID: 26142191
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of an anesthetized dog model of transient cardiac ischemia and rapid pacing: a pilot study for preclinical assessment of the potential for proarrhythmic risk of novel drug candidates.
    Damiano BP; van der Linde HJ; Van Deuren B; Somers Y; Lubomirski M; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2015; 72():72-84. PubMed ID: 25450838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
    Lu HR; Rohrbacher J; Vlaminckx E; Van Ammel K; Yan GX; Gallacher DJ
    Br J Pharmacol; 2010 May; 160(1):60-76. PubMed ID: 20331615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anisotropic effects of sodium channel blockers on the wavelength for ventricular excitation in dogs.
    Watanabe T; Yamaki M; Tachibana H; Yamauchi S; Kubota I; Tomoike H
    Jpn Circ J; 2000 Sep; 64(9):689-94. PubMed ID: 10981854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proarrhythmic effects of antiarrhythmic drugs.
    Goldstein RE; Tibbits PA; Oetgen WJ
    Ann N Y Acad Sci; 1984; 427():94-100. PubMed ID: 6588900
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk factors for the development of proarrhythmic events.
    Morganroth J
    Am J Cardiol; 1987 Apr; 59(11):32E-37E. PubMed ID: 3107364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion.
    Heisler BE; Ferrier GR
    J Pharmacol Exp Ther; 1996 Oct; 279(1):317-24. PubMed ID: 8859009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrocardiographic marker of the cardiac action potential triangulation induced by antiarrhythmic drugs in perfused guinea-pig heart.
    Osadchii OE
    Exp Physiol; 2022 Aug; 107(8):864-878. PubMed ID: 35561081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
    Osadchii OE
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):240-51. PubMed ID: 24220314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of flecainide safety in patients with supraventricular arrhythmias.
    Wehling M
    Arzneimittelforschung; 2002; 52(7):507-14. PubMed ID: 12189773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Worsening of ventricular arrhythmia in the dynamic ECG in patients treated with anti-arrhythmia drugs].
    Lanza GA; Tamburi S; Mondello Malvestiti FM; Rebuzzi AG; Lucente M
    Cardiologia; 1988 Jun; 33(6):613-8. PubMed ID: 3139292
    [No Abstract]   [Full Text] [Related]  

  • 14. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.
    Morganroth J; Horowitz LN
    Am J Cardiol; 1984 Feb; 53(5):89B-94B. PubMed ID: 6695821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.
    Skibsbye L; Ravens U
    Card Electrophysiol Clin; 2016 Jun; 8(2):395-410. PubMed ID: 27261830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge.
    Veeraraghavan R; Poelzing S
    Cardiovasc Res; 2008 Mar; 77(4):749-56. PubMed ID: 18056761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia.
    Kim HS; Pak HN; Park JS; Kim SS
    Pacing Clin Electrophysiol; 2013 Mar; 36(3):e84-6. PubMed ID: 21029131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects.
    Kidwell GA; Gonzalez MD
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):621-32. PubMed ID: 7681909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.